Sign In
Buy TSHA
$5.86
-0.0150 (-0.255%)
At Close: Jul 31, 2026
Taysha Gene Therapies to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 16
05:00pm, Monday, 09'th Aug 2021
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tr
Taysha Gene Therapies to Participate in Upcoming August Investor Healthcare Conferences
07:00am, Monday, 02'nd Aug 2021
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivitol-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tr
What 8 Analyst Ratings Have To Say About Taysha Gene Therapies
02:53pm, Friday, 16'th Jul 2021
Analysts have provided the following ratings for Taysha Gene Therapies (NASDAQ:TSHA) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 1 1 0 Somewhat Bullish 0 0 3
Taysha Gene Therapies to Participate in Upcoming July Investor Healthcare Conference
07:00am, Thursday, 08'th Jul 2021
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tr
What 9 Analyst Ratings Have To Say About Taysha Gene Therapies
11:37am, Thursday, 24'th Jun 2021
Taysha Gene Therapies (NASDAQ:TSHA) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 1 0 1 Somewhat Bullish 0 2 1 1 Indi
Taysha Gene Therapies to Participate in Upcoming May Investor Healthcare Conferences
06:15pm, Wednesday, 12'th May 2021
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the t
Taysha Gene Therapies' (TSHA) CEO RA Session II on Q1 2021 Results - Earnings Call Transcript
02:49pm, Tuesday, 11'th May 2021
Taysha Gene Therapies' (TSHA) CEO RA Session II on Q1 2021 Results - Earnings Call Transcript
Taysha Gene Therapies' Rett Syndrome Candidate Shows Encouraging Action In Animal Studies, Human Trial To Start By 2021
01:17pm, Monday, 10'th May 2021
Taysha Gene Therapies Inc (NASDAQ: TSHA) has announced the online publication of new preclinical data for TSHA-102 in Rett syndrome. The data will be included in the May edition of Brain, a peer-re
What's Going On With MOSY Stock And TSHA Stock?
03:08pm, Monday, 12'th Apr 2021
MoSys Inc. (NASDAQ: MOSY) shares are trading higher after the company announced it has expanded its patent portfolio through the purchase of five patents in the area of search and classification algor
Taysha Gene Therapies Stock Is Trading Higher After Buying Rights To New Gene Therapy Candidate For Neurodegenerative Disease
11:47am, Monday, 12'th Apr 2021
Taysha Gene Therapies Inc (NASDAQ: TSHA) has unveiled a deal for global rights to the AAV9 gene therapy program, now known as TSHA-120, to treat giant axonal neuropathy (GAN) Under the terms of th
TSHA Stock: Over 7% Increase Intraday Explanation
09:31am, Monday, 12'th Apr 2021
The stock price of Taysha Gene Therapies Inc (NASDAQ: TSHA) increased by over 7% during intraday trading this morning. This is why it happened.
Taysha Gene Therapies Announces Participation in Upcoming March Investor Healthcare Conferences
07:00am, Thursday, 11'th Mar 2021
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the t
Taysha Gene Therapies to Release Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 3
07:00am, Monday, 01'st Mar 2021
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene ther
Taysha Gene Therapies Announces Support of Rare Disease Day 2021
07:00am, Friday, 26'th Feb 2021
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the t
Taysha Gene Therapies Highlights Strategic Priorities and Provides 2021 Business Outlook
07:00am, Monday, 01'st Feb 2021
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene ther
